⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Figure S3 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics

Matilde Bocci Lucrezia Principi Dario Neri Samuele Cazzamalli Ettore Gilardoni Andrea Galbiati

View at Publisher

Ask AI

Bookmark

Share

Key Points

Body weight changes were observed in mice with tumors, indicating treatment response.
The mean body weight loss was recorded as ±SEM, based on different MMAE dosages.
Observational analysis involved mice receiving intravenous injections of MMAE conjugates at varying doses.
Findings highlight the need for further investigation into tailored drug release kinetics in tumor therapy.

Implication

Experimental results show body weight changes in tumor model mice after treatment with MMAE conjugates, indicating potential effectiveness.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bocci et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21aeb https://doi.org/10.1158/1535-7163.30255509

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S4 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics2025
2Figure S2 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics2025
3Data from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics2025
4Figure S6 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics2025
5Figure S5 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics2025

More related papers

Supplementary Information from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics2025
Figure S1 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics2025
FIGURE 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein2024